Evidence map›Paper›PMID 42227896›Full record

Observational studyEpilepsia2026

Add-on treatment with vinpocetine reduces seizure frequency and improves comorbidities in patients with loss-of-function γ-aminobutyric acid type A receptor variants.

Cathrine E Gjerulfsen, Vivian W Y Liao, Tomasz S Mieszczanek, Anne V Jakobsen, Elena Gardella, Kern Olofsson, Marina Nikanorova, Allan Bayat, Sebastian Ortiz, Sarah Weckhuysen and 6 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Epilepsia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Cathrine E GjerulfsenDepartment of Epilepsy Genetics and Personalized Medicine, Danish Epilepsy Centre, Filadelfia (member of European Reference Network EpiCARE), Dianalund, Denmark.ORCID https://orcid.org/0000-0002-3419-3133
Vivian W Y LiaoBrain and Mind Centre, School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
Tomasz S MieszczanekDepartment of Child Neurology, Danish Epilepsy Centre, Dianalund, Denmark.
Anne V JakobsenDepartment of Interdisciplinary Health Research, Danish Epilepsy Centre, Dianalund, Denmark.
Elena GardellaDepartment of Epilepsy Genetics and Personalized Medicine, Danish Epilepsy Centre, Filadelfia (member of European Reference Network EpiCARE), Dianalund, Denmark.ORCID https://orcid.org/0000-0002-7138-6022
Kern OlofssonDepartment of Child Neurology, Danish Epilepsy Centre, Dianalund, Denmark.
Marina NikanorovaDepartment of Child Neurology, Danish Epilepsy Centre, Dianalund, Denmark.
Allan BayatDepartment of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.ORCID https://orcid.org/0000-0003-4986-8006
Sebastian OrtizDepartment of Epilepsy Genetics and Personalized Medicine, Danish Epilepsy Centre, Filadelfia (member of European Reference Network EpiCARE), Dianalund, Denmark.
Sarah WeckhuysenNeurology Department, University Hospital Antwerp, Antwerp, Belgium.
Cecilie Johannessen LandmarkDepartment of Pharmacy, Oslo Metropolitan University, Oslo, Norway.ORCID https://orcid.org/0000-0002-0877-8912
Orrin DevinskyDepartment of Neurology, NYU Langone Medical Center, New York, New York, USA.ORCID https://orcid.org/0000-0003-0044-4632
Mary ChebibBrain and Mind Centre, School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
Philip K AhringBrain and Mind Centre, School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
Guido RubboliDepartment of Epilepsy Genetics and Personalized Medicine, Danish Epilepsy Centre, Filadelfia (member of European Reference Network EpiCARE), Dianalund, Denmark.ORCID https://orcid.org/0000-0002-5309-2514
Rikke S MøllerDepartment of Epilepsy Genetics and Personalized Medicine, Danish Epilepsy Centre, Filadelfia (member of European Reference Network EpiCARE), Dianalund, Denmark.ORCID https://orcid.org/0000-0002-9664-1448

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe semisynthetic compound vinpocetine has gained attention as a potential precision medicine for developmental and epileptic encephalopathies caused by loss-of-function (LoF) variants in γ-aminobutyric acid type A (GABA

methodsPatients initiated treatment with vinpocetine between 2018 and 2025 at the Danish Epilepsy Centre or abroad. Clinical data were collected from medical records, seizure diaries, and neuropsychological assessments. The modulatory efficacy of vinpocetine was investigated using electrophysiological studies.

resultsNine patients harboring eight GABA SIGNIFICANCE: Adjunctive vinpocetine shows promise as a targeted therapy for patients with GABA

Indexed as

AnticonvulsantsEpilepsyReceptors, GABA-ASeizuresVinca AlkaloidsAdolescentAdultChildComorbidityElectroencephalographyFemaleHumansMaleRetrospective StudiesTreatment OutcomeYoung AdultAnticonvulsantsReceptors, GABA-AVinca AlkaloidsvinpocetineCavintoncomorbiditiesdevelopmental and epileptic encephalopathies (DEE)precision medicine

Identifiers

PMID42227896
PMCPMC13525584

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.